Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Tesamorelin cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: Tesamorelin has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

  1. Two multicenter, randomized, double-blind, placebo-controlled trials (412 and 404 participants) each had a 26-week main phase in which participants received 2 mg of the original EGRIFTA formulation or placebo once daily (2:1), followed by a 26-week extension in which tesamorelin-treated completers were re-randomized to tesamorelin or placebo 1.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Tesamorelin combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Tesamorelin cycle length?
No cycle is defined. Tesamorelin is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Tesamorelin?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Tesamorelin dosing reference Full research page

References

  1. EGRIFTA WR (tesamorelin) for injection, prescribing information (revised 03/2025) FDA label (DailyMed). 2025
  2. EGRIFTA SV (tesamorelin) for injection, prescribing information (revised 03/2024) FDA label (DailyMed). 2024
  3. Metabolic effects of a growth hormone-releasing factor in patients with HIV N Engl J Med. 2007
  4. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data J Clin Endocrinol Metab. 2010
  5. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial JAMA. 2014
  6. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial Lancet HIV. 2019
  7. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  8. PubChem compound record for tesamorelin PubChem. 2026